SCHEMBL20980413

SCHEMBL20980413

CCCOCCOCCOCCOCCOCCC(N)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
SOAT1 P35610 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
FAAH O00519 1/20 0.38
TP53 P04637 1/20 0.38
CNR1 P21554 1/20 0.35
HSD17B10 Q99714 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.33
TSHR P16473 2/20 0.33
ALOX15 P16050 1/20 0.33
THRB P10828 1/20 0.32
HTT P42858 1/20 0.32
MAPT P10636 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
DGKA P23743 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27396526 1.00 CYP3A4 (0.38) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL15783570 1.00 CYP3A4 (0.38) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL26025176 1.00 CYP3A4 (0.38) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL19969031 1.00 CYP3A4 (0.38) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL4148199 0.98
SCHEMBL20234586 0.94 SOAT1 (0.34) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL21342076 0.91 CYP3A4 (0.39) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL22047274 0.87 TP53 (0.35) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL2576358 0.87 TP53 (0.35) CYP3A4SOAT1MEN1KMT2ACYP1A2
SCHEMBL22047244 0.87 TP53 (0.35) CYP3A4SOAT1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369744-A1 COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20190133948-A1 FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES NITTO DENKO CORPORATION (JP) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369744-A1 COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION PDE6C, UACA, EPHA2 CYP3A4 4375/4885SOAT1 3321/4885MEN1 1771/4885
US-20190133948-A1 FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES FUS, NSF, PGF CYP3A4 4782/4885SOAT1 2321/4885MEN1 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.